共 42 条
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells
被引:142
作者:
Zhao, Yong
[1
]
Jiang, Zhaoshun
[2
]
Zhao, Tingbao
[3
]
Ye, Mingliang
[4
]
Hu, Chengjin
[5
]
Yin, Zhaohui
[2
]
Li, Heng
[6
]
Zhang, Ye
[4
,7
]
Diao, Yalin
[4
]
Li, Yunxiang
Chen, Yingjian
[5
]
Sun, Xiaoming
[5
]
Fisk, Mary Beth
[8
]
Skidgel, Randal
[9
]
Holterman, Mark
[10
]
Prabhakar, Bellur
[11
]
Mazzone, Theodore
[1
]
机构:
[1] Univ Illinois, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60612 USA
[2] Gen Hosp Jinan Mil Command, Endocrinol Sect, Jinan 250031, Shandong, Peoples R China
[3] Gen Hosp Jinan Mil Command, Stem Cell Treatment Ctr, Jinan 250031, Shandong, Peoples R China
[4] Gen Hosp Jinan Mil Command, Sect Blood Transfus, Jinan 250031, Shandong, Peoples R China
[5] Gen Hosp Jinan Mil Command, Sect Mol Diagnost, Jinan 250031, Shandong, Peoples R China
[6] Jinan Cent Hosp, Sect Neuronol, Jinan 250020, Shandong, Peoples R China
[7] Jinan Tianhe Stem Cell Biotechol Co Ltd, Jinan 250055, Shandong, Peoples R China
[8] Texas Cord Blood Bank, San Antonio, TX 78201 USA
[9] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA
[10] Univ Illinois, Dept Surg, Peoria, IL 61603 USA
[11] Univ Illinois, Dept Immunol & Microbiol, Chicago, IL 60612 USA
来源:
关键词:
REGULATORY T-CELLS;
CUTTING EDGE;
DOUBLE-BLIND;
C-REL;
TOLERANCE;
THERAPY;
CD28;
GAD;
MECHANISMS;
UNIQUE;
D O I:
10.1186/1741-7015-10-3
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: Inability to control autoimmunity is the primary barrier to developing a cure for type 1 diabetes (T1D). Evidence that human cord blood-derived multipotent stem cells (CB-SCs) can control autoimmune responses by altering regulatory T cells (Tregs) and human islet beta cell-specific T cell clones offers promise for a new approach to overcome the autoimmunity underlying T1D. Methods: We developed a procedure for Stem Cell Educator therapy in which a patient's blood is circulated through a closed-loop system that separates lymphocytes from the whole blood and briefly co-cultures them with adherent CB-SCs before returning them to the patient's circulation. In an open-label, phase1/phase 2 study, patients (n = 15) with T1D received one treatment with the Stem Cell Educator. Median age was 29 years (range: 15 to 41), and median diabetic history was 8 years (range: 1 to 21). Results: Stem Cell Educator therapy was well tolerated in all participants with minimal pain from two venipunctures and no adverse events. Stem Cell Educator therapy can markedly improve C-peptide levels, reduce the median glycated hemoglobin A1C (HbA1C) values, and decrease the median daily dose of insulin in patients with some residual beta cell function (n = 6) and patients with no residual pancreatic islet beta cell function (n = 6). Treatment also produced an increase in basal and glucose-stimulated C-peptide levels through 40 weeks. However, participants in the Control Group (n = 3) did not exhibit significant change at any follow-up. Individuals who received Stem Cell Educator therapy exhibited increased expression of co-stimulating molecules (specifically, CD28 and ICOS), increases in the number of CD4(+)CD25(+)Foxp3(+) Tregs, and restoration of Th1/Th2/Th3 cytokine balance. Conclusions: Stem Cell Educator therapy is safe, and in individuals with moderate or severe T1D, a single treatment produces lasting improvement in metabolic control. Initial results indicate Stem Cell Educator therapy reverses autoimmunity and promotes regeneration of islet beta cells. Successful immune modulation by CB-SCs and the resulting clinical improvement in patient status may have important implications for other autoimmune and inflammation-related diseases without the safety and ethical concerns associated with conventional stem cell-based approaches.
引用
收藏
页数:11
相关论文